Showing results (1741-1750 of 1,960) with videos related to

Sort By:
Pageof 196
Journal of the National Cancer Institute. Monographs|November 17, 2005
Building a virtual cancer research organizationMark C Hornbrook, Gene Hart, Jennifer L Ellis, et al.
Blood Cancer Journal|November 5, 2016
Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cellsA Paulus, S Akhtar, T R Caulfield, et al.
Blood|July 16, 2016
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapyVindi Jurinovic, Robert Kridel, Annette M Staiger, et al.
Genome Research|November 12, 2021
Long-read assembly and comparative evidence-based reanalysis of Cryptosporidium genome sequences reveal expanded transporter repertoire and duplication of entire chromosome ends including subtelomeric regionsRodrigo P Baptista, Yiran Li, Adam Sateriale, et al.
Blood Cancer Discovery|November 15, 2021
Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom MacroglobulinemiaAkhilesh Kaushal, Ajay K Nooka, Allison R Carr, et al.
Blood|January 9, 2025
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 studyMax S Topp, Matthew Matasar, John N Allan, et al.
American Journal of Hematology|September 18, 2014
Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphomaThomas E Witzig, Matthew J Maurer, Thomas M Habermann, et al.
Iscience|June 1, 2023
Secreted ORF8 induces monocytic pro-inflammatory cytokines through NLRP3 pathways in patients with severe COVID-19Xiaosheng Wu, Michelle K Manske, Gordon J Ruan, et al.
Blood|July 31, 2020
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphomaNancy L Bartlett, Alex F Herrera, Eva Domingo-Domenech, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor CellsFatma Aboulnasr, Ashton Krogman, Rondell P Graham, et al.
Pageof 196